Abstract: This invention relates to methods for diagnosing Alzheimer's Disease (AD) by determining the level or function of insulin, insulin-like growth factors, their receptors and/or their downstream signaling molecules. The invention further relates to methods for the treatment of AD by administering an insulin agonist and an insulin-like growth factor agonist. The invention additionally provides an animal model of AD and methods of screening for agents useful in the treatment, amelioration, or prevention of AD.

Abstract: Nucleic acid molecule that comprise a hepatitis C nonstructural protein including specifically disclosed DNA sequences are disclosed. Pharmaceutical compositions that contain nucleic acid molecules comprising a hepatitis C nonstructural protein including a nucleotide sequence encoding NS3, NS4, or NS5, or a combination thereof, operably linked to regulatory elements functional in human cells are disclosed. Methods of immunizing individuals susceptible to or infected by hepatitis C virus comprising administering such pharaceutical compositions are disclosed.

Abstract: The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH.

Abstract: Thymosin-?1 is used as an adjuvant in combination with carmustine (BCNU) as an effective treatment for malignant glioblastoma.

Abstract: Nucleic acid molecule that comprise a hepatitis C nonstructural protein including specifically disclosed DNA sequences are disclosed. Pharmaceutical compositions that contain nucleic acid molecules comprising a hepatitis C nonstructural protein including a nucleotide sequence encoding NS3, NS4, or NS5, or a combination thereof, operably linked to regulatory elements functional in human cells are disclosed. Methods of immunizing individuals susceptible to or infected by hepatitis C virus comprising administering such pharmaceutical compositions are disclosed.

Abstract: The invention features a method of inhibiting tumor growth and/or tumor invasiveness in a mammal by administering to a mammal a compound (e.g., an antagonistic antibody) which inhibits expression or enzymatic activity of human aspartyl (asparaginyl) beta-hydroxylase (HAAH). The invention also features a method for diagnosing the growth of a malignant neoplasm (e.g., pancreatic cancer) in a mammal by contacting a tissue or bodily fluid from the mammal with an antibody which binds to a HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and/or detecting the antigen-antibody complex.

Abstract: The invention features a method for diagnosing and inhibiting growth of a malignant neoplasm in a mammal by contacting a cell or a bodily fluid of the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide. Methods of immunization to generate an HAAH-specific immune response are also within the invention.

Abstract: The invention features a non-transgenic model of Alzheimer's Disease, method for inducing prolonged in vivo gene expression in a mammal, and methods of inhibiting Alzheimer's Disease-associated neuronal cell death.

Abstract: This invention describes the use of thymosin to augment cellular immune responses to hepatitis C virus. Methods for immunizing a subject susceptable to hepatitis C virus infection against such infection, comprising administering to the subject one or more polynucleotides encoding one or more hepatitis C virus peptides, in combination with one or more thymosins, are disclosed. Compositions suitable for immunizing against hepatitis C virus, comprising one or more polynucleotides encoding one or more hepatitis C virus peptides, and one or more thymosins, are also disclosed.

Abstract: Disclosed is a method for treating or preventing Alzheimer's disease by restricting the level of metabolizable carbohydrate in the diet and/or administering to the patient an effective amount of an agent which reduces serum insulin levels.

Abstract: The invention relates to methods for preventing and treating disseminating cancers. Inhibition metastases of a primary tumor to a liver tissue is carried out by directly contacting a liver tissue with Taurolidine.

Abstract: Nucleic acid molecule that comprise an incomplete hepatitis C viral genome are provided. Pharmaceutical compositions that contain nucleic acid molecules comprising an incomplete hepatitis C viral genome including a nucleotide sequence encoding a complete hepatitis C core protein operably linked to regulatory elements functional in human cells are provided. Methods of immunizing individuals susceptible to or infected by hepatitis C virus comprising the step of administering such pharmaceutical compositions are provided.

Abstract: Nucleic acid molecule that comprise an incomplete hepatitis C viral genome including specifically disclosed DNA sequences are disclosed. Pharmaceutical compositions that contain nucleic acid molecules comprising an incomplete hepatitis C viral genome including a nucleotide sequence encoding a complete hepatitis C core protein operably linked to regulatory elements functional in human cells are disclosed.

Abstract: Nucleic acid molecule that comprise an incomplete hepatitis C viral genome including specifically disclosed DNA sequences are disclosed. Pharmaceutical compositions that contain nucleic acid molecules comprising an incomplete hepatitis C viral genome including a nucleotide sequence encoding a complete hepatitis C core protein operably linked to regulatory elements functional in human cells are disclosed. Methods of immunizing individuals susceptible to or infected by hepatitis C virus comprising the step of administering such pharmaceutical compositions are disclosed.

Abstract: A purified form of a DNA virus which has the following characteristics: molecular weight greater than 2.times.10.sup.6 Daltons; substantial immunoreactivity towards an anti-HBsAg monoclonal antibody obtained from cell line ATCC HB 8058; substantially no immunoreactivity towards an anti-HBsAg monoclonal antibody obtained from cell line ATCC CRL 8018; concentration dependent immunoreactivity towards polyclonal IgG anti-HBsAg antibodies, which increases with increased concentration of said DNA virus; discrete particulate form when observed by immunoelectron microscopy in the presence of IgM antibodies from cell line ATCC HB 8058; the DNA of said virus showing hybridization with DNA from hepatitis B viral DNA; and said DNA virus showing, in chimpanzees, infectivity having the characteristics of non A, non B hepatitis.